{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:48:11Z","timestamp":1794311291568,"version":"4.9.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ijantimicag.2021.106367","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T11:54:46Z","timestamp":1622202886000},"page":"106367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim\/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy"],"prefix":"10.1016","volume":"58","author":[{"given":"Shauna Jacobson","family":"Junco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Catherine","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9134-7346","authenticated-orcid":false,"given":"R. Brigg","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2021.106367_bib0001","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jac\/dkn301","article-title":"Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review","volume":"62","author":"Falagas","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0002","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/CMR.00019-11","article-title":"Stenotrophomonas maltophilia: an emerging global opportunistic pathogen","volume":"25","author":"Brooke","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0003","unstructured":"World Health Organization. Public health importance of antimicrobial resistance. WHO n.d. https:\/\/www.who.int\/drugresistance\/AMR_Importance\/en\/ (accessed August 20, 2020)."},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0004","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1473-3099(09)70083-0","article-title":"Stenotrophomonas maltophilia: an emerging opportunist human pathogen","volume":"9","author":"Looney","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0005","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-2180-10-102","article-title":"Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients","volume":"10","author":"Pompilio","year":"2010","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0006","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s10096-011-1459-8","article-title":"Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients","volume":"31","author":"Saugel","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0007","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jmii.2011.09.028","article-title":"A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan","volume":"45","author":"Wu","year":"2012","journal-title":"J Microbiol Immunol Infect"},{"issue":"32 Suppl 2","key":"10.1016\/j.ijantimicag.2021.106367_bib0008","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1086\/320183","article-title":"Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999)","author":"Gales","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0009","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3201\/eid1304.061378","article-title":"Global emergence of trimethoprim\/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes","volume":"13","author":"Toleman","year":"2007","journal-title":"Emerging Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0010","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/jac\/dkv456","article-title":"Monotherapy with minocycline or trimethoprim\/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections","volume":"71","author":"Hand","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0011","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1093\/jac\/dkw327","article-title":"Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections","volume":"71","author":"Jacobson","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0012","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. Document M100-S26. 2019."},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0013","article-title":"Evaluation of trimethoprim\/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, and ceftazidime alone and in combinations for SXTsusceptible and SXT-resistant Stenotrophomonas maltophilia by in vitro time-kill experiments","volume":"11","author":"Wei","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0014","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1086\/665731","article-title":"The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"33","author":"Stevens","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0015","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","year":"2012","journal-title":"Kidney International Supplements"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0016","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/MLR.0b013e31806518ac","article-title":"Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases","volume":"45","author":"Curtis","year":"2007","journal-title":"Med Care"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0017","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0018","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/AAC.01682-13","article-title":"Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?","volume":"58","author":"Cho","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0019","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/AAC.01324-13","article-title":"Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jgar.2017.09.015","article-title":"Sulfamethoxazole\/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections","volume":"12","author":"Watson","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0021","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.cmi.2018.11.008","article-title":"Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis","volume":"25","author":"Ko","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0022","doi-asserted-by":"crossref","first-page":"e00788","DOI":"10.1128\/AAC.00788-19","article-title":"Clinical and microbiologic outcomes in patients with monomicrobial Stenotrophomonas maltophilia infections","volume":"63","author":"Nys","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0023","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10096-007-0279-3","article-title":"Antimicrobial therapy for Stenotrophomonas maltophilia infections","volume":"26","author":"Nicodemo","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0024","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3346\/jkms.2013.28.1.62","article-title":"Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates","volume":"28","author":"Chung","year":"2013","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3109\/00365548.2012.732240","article-title":"Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates","volume":"45","author":"Church","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0026","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1179\/1973947814Y.0000000168","article-title":"Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations","volume":"26","author":"Hu","year":"2014","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0027","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3109\/23744235.2015.1064542","article-title":"A Monte Carlo pharmacokinetic\/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia","volume":"47","author":"Wei","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0028","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1128\/AAC.40.12.2859","article-title":"Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model","volume":"40","author":"Garrison","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0029","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/AAC.48.3.946-953.2004","article-title":"Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model","volume":"48","author":"Ba","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0030","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/jac\/dkz116","article-title":"Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia","volume":"74","author":"Shah","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106367_bib0031","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13054-019-2649-5","article-title":"Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study","volume":"23","author":"Guerci","year":"2019","journal-title":"Crit Care"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857921001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857921001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:39:55Z","timestamp":1760377195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857921001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0924857921001205"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106367","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim\/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106367"}}